Cat. No. 6293
Alternative Names: ELA (19-32) (human), ELABELA
Biological ActivityPotent apelin (APJ) receptor agonist (Ki = 0.93 nM). ELABELA analog. Activates Gαil pathway and β-arrestin-2 recruitment . Reduces arterial pressure in rat hearts. Active in vivo. ELA-14 negative control (Cat.No. 6294) available.
Licensing InformationSold under agreement from the Agency for Science, Technology and Research (A*STAR), ETPL, and affiliates including the Institute of Medical Biology.
(Modifications: X = Glp)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Murza et al (2016) Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J.Med.Chem. 59 2962. PMID: 26986036.
If you know of a relevant reference for ELA-14 (human) please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses ELA-14 (human) from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: ELA-14 (human), supplier, Apelin, receptor, agonist, agonism, APJ, ELABELA, analog, beta-arrestin-2, b-arrestin-2, β-arrestin-2, Gail, Galphail, Gαil, blood, pressure, active, in, vivo, Tocris Bioscience, Apelin Receptor Agonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).Retrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
November 8 - 10, 2017